CLINICAL TRIALS & OUTCOME MEASURES

(154) In Vitro Responses OF F508DEL Human Nasal Epithelial Cells Correlate to Clinical Improvement to ELEXACAFTOR/TEZACAFTOR/IVACAFTOR

(155) Longitudinal Improvements in Clinical and Functional Outcomes following Initiation of Elexacaftor/Tezacaftor/Ivacaftor in Patients with Cystic Fibrosis

(156) Multicenter Validation of the CF-ABLE Score as a Predictor of Outcome and Therapeutic Response in Cystic Fibrosis

(158) Validation of the Q-Life app: an individualized patient-reported outcome measure to assess quality of life

(159) A Qualitative Examination of Participation in the SIMPLIFY Treatment Withdrawal Trial

(162) The Acceptability and Usability of a Soft, Flexible, Wearable Device for Cough Detection in Pediatric Cystic Fibrosis Patients

(163) Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in children 6 years and older with cystic fibrosis and ≥1 F508del allele: 96-week interim results from an open-label extension study

(166) Measuring adherence to chronic therapies over the first year of treatment with Elexacaftor/Tezacaftor/Ivacaftor in people with Cystic Fibrosis (CF)

(167) Two Year Respiratory Culture and Pulmonary Function Outcomes in Patients on Elexacaftor/Tezacaftor/Ivacaftor

(168) Results from APPLAUD Phase 2 Study with Pro-Resolution Drug Candidate LAU-7b in Adults with Cystic Fibrosis

(169) A Phase 4, Fully Decentralized Clinical Trial to Evaluate Physical Activity and Cough Frequency in Patients with Cystic Fibrosis Using Wearable Technology

(170) Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from an open-label extension study

(173) Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in children with cystic fibrosis: The Pediatric PROMISE study

(174) Proteomic analysis identifies physiological characteristics at baseline, one, and six months that segregate lung function response to ivacaftor.

(175) QuestionCF 2022: refreshing the top 10 research priorities for clinical research in Cystic Fibrosis

(176) How frequently should the lung clearance index be measured in children with cystic fibrosis?

(178) Towards targeted exhaled breath analysis for young children in CF care to detect bacteria in the lungs

(181) Estimating personalized lung function trends from routine clinical care to facilitate analysis of daily data capture through remote technologies

(182) A Qualitative Needs Assessment of People with CF and Research Coordinators to Inform Future Clinical Trials Incorporating Home Spirometry as an Endpoint

(184) Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on Lung Clearance Index and Magnetic Resonance Imaging in Patients with Cystic Fibrosis and One or Two F508del Alleles

(185) Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for F508del-CFTR and a gating or residual function mutation

(186) Pilot Study of Sweat Induction Using Pilocarpine Microneedles During Sweat Test in Healthy Adults Without Cystic Fibrosis

(187) Use of Sweat Chloride Testing to Assess Adherence to and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor Treatment in a Pediatric Cystic Fibrosis Clinic

(694) Greater Reductions in Sweat Chloride with CFTR Modulator Use are Associated with Improved Clinical Outcomes